Matthias Liechti
Professor of Clinical Pharmacology
Data updated
Research Footprint
Matthias Liechti appears in 93 tracked papers (1998–2026) and 3 clinical trials, most studied alongside LSD, MDMA and Psilocybin, across Healthy Volunteers, Anxiety Disorders and Medicinal Chemistry & Drug Development.
Most-cited paper: Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naıve healthy volunteers (450 citations).
Frequent co-authors: Friederike Holze, Patrick Vizeli and Yasmin Schmid.
Background & Research
Matthias Liechti is a Swiss scientist and physician, currently serving as a Professor of Clinical Pharmacology and Internal Medicine at the University of Basel. He heads the Liechti Lab at the University Hospital Basel, which is globally recognized for its rigorous clinical trials on the acute effects of LSD, MDMA, and psilocybin. His research interests span psychopharmacology, pharmacokinetics, and the development of novel treatments for psychiatric disorders.
Key Impact
World-leading clinical researcher focusing on the human pharmacology of MDMA, LSD, and other psychoactive substances at the University of Basel.
Collaboration Network
66 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Matthias Liechti is associated with.
University of Basel
academicProfessor; Head of Clinical Pharmacology & Toxicology, University Hospital Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →